Stage I triple-negative solid basaloid adenoid cystic breast cancer treated with mastectomy and oral chemotherapy

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: Current tumor was triple-negative with high Ki-67 and c-kit/CK7 staining. Prior breast cancer was ER-positive, HER2-positive, PR-negative.

One year after mastectomy and postoperative tegafur-gimeracil-oteracil potassium, she was recovering well without signs of metastasis.

PubMed CentralRead more →

ALK-Positive Metastatic Lung Cancer Responding to Lorlatinib During Hemodialysis

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: ALK rearrangement 80%; EGFR and BRAF negative; ROS1 negative; PD-L1 negative

Metastatic Site: brain

After about 1 year of lorlatinib, imaging was almost compatible with a complete response, brain MRI showed no active lesions, and she continued treatment with manageable high cholesterol as the main reported side effect.

PubMed CentralRead more →

Metastatic Colorectal Cancer With Severe Hypocalcemia After Denosumab

Patient Info: Anonymized, male, 70+ | Stage IV

Biomarkers: MLH1, PMS2, MSH2 and MSH6 retained; DPYD wild type

Metastatic Site: bone, liver

Bone imaging in November 2023 showed progression with more extensive skeletal involvement while he remained under care for metastatic colorectal cancer.

PubMed CentralRead more →

MET Y1003N-Mutant Lung Adenocarcinoma Responding to Tepotinib

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: MET mutation

Metastatic Site: bone

Tepotinib produced an 8-month response after many earlier treatments, but the cancer later recurred and she died about 3 years after treatment began.

PubMed CentralRead more →

EGFR-Mutant Lung Cancer With Pleomorphic Transformation Treated With Local Surgery

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR L858R mutation; PD-L1 less than 1% initially and greater than 75% after transformation

Metastatic Site: brain

Nine months after surgery for isolated progression, no recurrence had been seen and she remained on osimertinib.

PubMed CentralRead more →

HER2-Positive Breast Cancer With Metastatic Progression and Drug-Induced Lupus During T-DM1

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-positive

Metastatic Site: bones, axillary lymph nodes, intra-abdominal lymph…

More than 5 years after her March 2018 diagnosis, she was living with metastatic breast cancer, but T-DM1 had been stopped after disease progression in 2023.

PubMed CentralRead more →

Metastatic breast cancer with receptor evolution: sequential endocrine, immunotherapy, CDK4/6, and antibody-drug conjugate treatment

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Markers changed over time: initial tumor ER-positive/HER2-negative; local recurrence triple-negative/HER2-low; pleural fluid ER-negative.

Metastatic Site: mediastinal lymph nodes, pleura; pulmonary nodules…

More than 7 years after diagnosis, she remained on sequential systemic therapy for metastatic breast cancer, with at least a partial response 3 months after starting sacituzumab govitecan for presumed triple-negative pleural disease.

PubMed CentralRead more →

Stage IV cecum cancer with liver and ovarian metastases: ramucirumab-related nephrotic syndrome and glomerular microangiopathy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Cancer biomarkers were not reported. Kidney injury workup showed severe protein leakage and biopsy-proven glomerular microangiopathy.

Metastatic Site: liver, right ovary

The liver metastasis shrank after XELOX plus bevacizumab and metastatic liver/ovarian sites were resected, but ramucirumab-based second-line therapy was stopped after nephrotic syndrome and severe glomerular microangiopathy; blood pressure and proteinuria improved with telmisartan.

PubMed CentralRead more →

Therapy-related acute promyelocytic leukemia during lung cancer treatment

Patient Info: Anonymized, Male, 70+

Biomarkers: Therapy-related APL with t and PML/RARA fusion; CD33 positive

The patient died 6 hours after symptom onset on day 6 of induction therapy for therapy-related acute promyelocytic leukemia.

PubMed CentralRead more →

Stage IV ALK Lung Adenocarcinoma: Shirley's Patient Story

Patient Info: Shirley, Female, Under 40 | Stage IV

Biomarkers: ALK mutation

As of December 2024, Shirley was living with Stage IV ALK-positive lung adenocarcinoma and had stable disease on a fourth-generation ALK inhibitor clinical trial that began in July 2024.

The Patient StoryRead more →

How Clinical Trials Helped Me Fight Stage 4 Cancer

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ALK-positive / ALK-rearranged

Metastatic Site: Not specified

As of December 2024, this anonymized patient described living 10.5 years with Stage IV non-small cell lung cancer and said her current clinical-trial treatment was working, with tumors shrinking.

The Patient StoryRead more →

ROS1-Positive Stage III Lung Adenocarcinoma With Pathologic Complete Response

Patient Info: Anonymized, male, 40s | Stage III

Biomarkers: ROS1 fusion-positive

Surgery found no residual cancer cells or involved lymph nodes, and no recurrence was detected during 10 months of crizotinib treatment and follow-up.

PubMed CentralRead more →

Doctors Assured Me It Wasn’t Cancer!

Patient Info: Shirley, Female, Under 40 | Stage IV

Biomarkers: ALK-rearranged

Metastatic Site: mediastinum, pleura

Shirley was living with Stage IV ALK-positive lung cancer on a phase 2 ALK clinical trial; scans remained stable after 2 scan sets, but the large mass persisted.

The Patient StoryRead more →

Small Cell Lung Cancer With Paraneoplastic Cushing Syndrome Treated With Immunochemotherapy

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1 negative; low tumor mutation burden; microsatellite stable

Metastatic Site: liver, abdominal wall, left ilium

He lived 20 months after diagnosis. After repeated treatment responses and later progression, he died in September 2023 from respiratory and cardiac failure during a severe infection following treatment-related myelosuppression.

PubMed CentralRead more →

Stage 4 HR-positive breast cancer: stable disease on ribociclib

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: left iliac bone

Metastatic HR-positive, HER2-negative breast cancer remained without progression as of October 2024 while she continued ribociclib 400 mg plus letrozole after SBRT to a left iliac bone metastasis.

PubMed CentralRead more →

Lung Cancer: Jill's Patient Story

Patient Info: Jill Feldman, Female

Biomarkers: Biomarker testing performed; specific personal biomarker not reported

As of December 2024, Jill described living with lung cancer for 15 years and credited biomarker testing and targeted therapies with helping her live longer, although no current NED status was stated.

The Patient StoryRead more →

Colon cancer recurring in the spleen with a serious splenic abscess

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: KRAS wild-type, NRAS wild-type, BRAF wild-type

Metastatic Site: spleen

More than 5 years after his 2016 colectomy, he was treated for metastatic recurrence. Disease was assessed as stable during systemic therapy, and he later recovered well after splenectomy for confirmed splenic metastasis.

PubMed CentralRead more →

Stage III HER2-Positive Breast Cancer Complicated by Systemic Sclerosis During Treatment

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: HER2-positive

At 3-month follow-up after anticancer treatment was stopped, no breast-cancer recurrence or metastasis was detected.

PubMed CentralRead more →

Stage IV lung adenocarcinoma: ROS1 fusion detected after immunotherapy resistance and partial response to entrectinib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial lung adenocarcinoma markers supported lung origin; PD-L1 <1%, no target found at first. Later testing found CD74-ROS1 fusion.

Metastatic Site: brain, bilateral lung lesions

As of December 2024, repeat imaging after entrectinib showed partial response in lung disease and regression of brain metastases, with the patient stable and willing to continue treatment.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Leah's Patient Story

Patient Info: Leah Phillips, Female, 40s | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Not reported

As of December 2024, Leah was recovering well a few weeks after right-middle-lobe lobectomy, but remained a Stage IV EGFR-mutated lung cancer patient needing ongoing treatment and follow-up.

MD AndersonRead more →

Stage IV ROS1 Non-Small Cell Lung Cancer: Ashley's Survivor Story

Patient Info: Ashley, Female, Under 40 | Stage IV

Biomarkers: ROS1-rearranged

Metastatic Site: spine/bone

As of December 2024, Ashley described herself as having no evidence of active disease while continuing nightly ROS1-targeted therapy.

The Patient StoryRead more →

Stage III BRCA1 Ovarian Cancer: Carla's Survivor Story

Patient Info: Carla Peoples, female | Stage III

Biomarkers: BRCA1 mutation

She was cancer-free after surgery and 6 rounds of chemotherapy and continued olaparib maintenance with CA-125 blood testing every 3 weeks.

MD AndersonRead more →

Stage IV luminal B breast cancer with liver, bone, and bone marrow metastases

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER 90% positive; PR 20% positive; HER2-negative; Ki-67 60%; luminal B

Metastatic Site: liver, bone, bone marrow

The patient had marked clinical and hematologic improvement on leuprorelin, letrozole, ribociclib, and zoledronic acid, with sustained complete remission reported for 4 months from September to December 2023 and monthly follow-up advised.

PubMed CentralRead more →

Metastatic EGFR-positive lung adenocarcinoma: osimertinib cardiomyopathy managed with SGLT2 inhibitor support

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR-positive; specific EGFR sequence variant not reported in extracted case text

As of December 2024, he remained clinically stable and asymptomatic 12 months after osimertinib rechallenge with empagliflozin, losartan, metoprolol, and close cardiac monitoring; the extracted case focuses on cardiotoxicity management rather than tumor response.

PubMed CentralRead more →